Skip to main content
Premium Trial:

Request an Annual Quote

Metdia to Commercialize Metabolon Diabetes Tests in Europe

NEW YORK (GenomeWeb) – Metabolon today announced a partnership with Spanish biomedical firm Metdia Biotech to commercialize the Quantose IR and Quantose IGT prediabetes tests in 14 European countries.

The two Metabolon tests are for assessing the risk of a patient developing prediabetes and/or type 2 diabetes. They also are for monitoring, and with appropriate intervention, preventing the two ailments. Metdia will market them to hospitals and clinical laboratories in Spain, Portugal, France, Italy, the UK, Germany, Switzerland, Sweden, Norway, Denmark, Finland, the Netherlands, Belgium, and Austria.

Earlier this year, Metabolon announced collaborations and licensing agreements covering the Quantose IR test in Mexico and Latin America. Metabolon President and CEO John Ryals said in a statement that the partnership with Metdia represents "an important next step" in expanding access to the Quantose technology beyond the US.

Quantose IR is a laboratory-developed test for evaluating insulin resistance. The blood-based test uses insulin and three non-glycemic biomarkers to assess the risk of a patient progressing to prediabetes. It does so at an earlier phase than traditional glycemic measures, such as hemoglobin A1c, Metabolon said.

Quantose IGT is for assessing impaired glucose tolerance and may be used as an alternative to an oral glucose tolerance test to identify patients who may be candidates for such a test.

Financial and other terms of the agreement with Metdia were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.